Spotting Fatty Liver: The Condition 1 in 3 Singaporeans May Have Without Knowing It

Spotting Fatty Liver: The Condition 1 in 3 Singaporeans May Have Without Knowing It

An estimated 1 in 3 people in Singapore have fatty liver, often without symptoms. Here is what MASLD means, what to track, and why early action matters.

· 7 min read

An estimated 1 in 3 people in Singapore have fatty liver, clinically known as MASLD or metabolic-associated steatotic liver disease. It's one of the most common metabolic conditions in the country. Most people who have it don't realise it, because in its early stages, it produces no symptoms at all.

That's worth knowing not because it's cause for alarm, but because early-stage fatty liver is one of the most reversible conditions in medicine. The liver is remarkably forgiving, if you catch it in time.

What MASLD Is — And What Drives It

MASLD means there's more fat in your liver than there should be, typically more than 5% of the liver's weight. You may also see the older name, NAFLD (non-alcoholic fatty liver disease); they describe essentially the same condition, renamed in 2023 to better reflect its metabolic roots.

The primary driver is insulin resistance. When your cells become less responsive to insulin, your body compensates by producing more of it — and elevated insulin promotes fat storage, including in the liver. Excess caloric intake (particularly refined carbohydrates and sugars), sedentary habits, and genetic predisposition all contribute.

One misconception worth addressing: MASLD is not caused by alcohol. Many people associate liver disease with drinking and assume this does not apply to them, but MASLD is metabolic and driven by how your body processes energy, not by what you drink.

Why Singapore, Specifically

MASLD is a global issue, but Singapore's numbers are striking. A 2023 review in Clinical and Molecular Hepatology put Singapore's NAFLD prevalence at 40.43%, and Southeast Asia as a region at 42%, which is the highest of any Asian subregion. Several factors make this population particularly susceptible.

Lower BMI, same risk. A 2019 global meta-analysis found that NAFLD patients in Asia had a mean BMI of 26.2, compared to 29.9 to 31.0 in Europe and the Americas. A Journal of Hepatology review estimated that 8–19% of Asians with BMIs below 25 have NAFLD. The reason is body composition: at the same BMI, Asian populations tend to accumulate more visceral fat, which is the fat stored around organs, including the liver, than Western populations. It's this visceral fat, not body weight, that drives hepatic fat accumulation.

Ethnic variation. Indian and Malay populations in Singapore show higher rates of MASLD than Chinese Singaporeans. A 2020 disease modelling study estimated that Malay and Indian populations experience NAFLD at rates 1.6 to 1.7 times higher than the Chinese population, driven partly by genetic differences in insulin resistance and visceral fat storage.

Dietary patterns. Singapore's food environment is calorie-dense and carbohydrate-heavy. White rice as a staple, sweetened drinks, frequent meals rich in refined carbs — the National Nutrition Survey bears this out, with refined grains accounting for 83% of carbohydrate intake and sugar-sweetened beverages remaining the single largest source of dietary sugar. Over time, these patterns create exactly the metabolic conditions under which MASLD develops.

The Metabolic Connection

MASLD rarely exists in isolation. It's one expression of a broader metabolic pattern. Where you find fatty liver, you'll almost always find some combination of elevated triglycerides, low HDL cholesterol, rising HbA1c or fasting glucose, and increased visceral fat. It's not just a liver issue — it's a metabolic signal. A recent meta-analysis found that MASLD is associated with a 54% increased risk of cardiovascular events and a 46% increase in cardiovascular mortality. This is not because fatty liver causes these directly, but because they share the same underlying driver: insulin resistance.

Your liver may be the first organ to show you what is coming, if you are looking.

What to Track, and Why Trends Matter

Detection relies entirely on biomarkers. The key markers fall into two groups:

Liver enzymes — the direct signal:

ALT (alanine aminotransferase): The most liver-specific marker. Elevated ALT is often the first sign that something is happening in the liver. Mild elevations — even within the "normal" range — can be clinically meaningful, especially in lean individuals.

AST (aspartate aminotransferase): Less specific to the liver (it's also present in muscle and heart tissue), but the ALT-to-AST ratio provides useful context. In MASLD, ALT is typically higher than AST; if that ratio flips, it may suggest more advanced disease.

GGT (gamma-glutamyl transferase): Elevated GGT alongside elevated ALT strengthens the case for liver involvement. It's also a marker of oxidative stress and insulin resistance.

Metabolic markers — the context:

Triglycerides, HbA1c, and fasting glucose. Elevated readings across these combined with liver enzyme changes strongly suggest MASLD and point to the broader metabolic picture.

Most standard health screening panels already include these markers. The issue is rarely that the data isn't collected, but that results are viewed in isolation.

A single mildly elevated ALT is easy to set aside. However, three readings over 18 months, with each a little higher, form a trend. Trends tell a story that snapshots cannot.

This is where longitudinal tracking changes the picture. When you upload health reports to Genie's Health Locker, biomarkers like liver enzymes show up under Gut and Metabolic Health, or under Liver Function in All Biomarkers, and are tracked across reports over time. The pattern becomes visible. Not as a diagnosis, but as usable information you can act on and share with your doctor.

What You Can Actually Do

Early-stage MASLD is reversible. Lifestyle intervention is highly effective.

Diet: Reduce refined carbohydrates and added sugars, which are the primary dietary drivers of liver fat. Shift toward whole grains, vegetables, and protein. You don't need a special "liver diet"; what's good for metabolic health is good for liver health.

Movement: 150 minutes per week of moderate activity, even brisk walking, has been shown to reduce liver fat independent of weight loss. A 2024 clinical trial found that this level of exercise led to a threefold increase in disease resolution compared to standard care. Resistance training helps improve insulin sensitivity.

Weight management: A 5–10% reduction in body weight significantly reduces liver fat. For someone at 75 kg, that is 3.5 to 7.5 kg, which is achievable and impactful.

Track your numbers: Repeat your liver and metabolic panels at 6-month intervals if any markers were elevated. Upload your reports to Genie's Health Locker to track these biomarkers over time. If you have a wearable connected, you can Ask Genie to help you correlate your results with your lifestyle habits.

FAQs

Can fatty liver be reversed?
Yes. Early-stage fatty liver is highly reversible through lifestyle changes including dietary improvements, regular physical activity, and modest weight loss (5–10% of body weight). The liver can recover well when metabolic drivers are addressed before significant scarring develops.
What blood tests detect fatty liver?
Liver enzymes, ALT, AST, and GGT, are the primary markers. Combined with metabolic markers (triglycerides, HbA1c, fasting glucose), they provide a strong indication. Imaging such as ultrasound or FibroScan can confirm and assess severity.
Can you have fatty liver if you're not overweight?
Yes. "Lean MASLD" is more common in Asian populations. A Singapore Medical Journal review noted that nearly 20% of non-obese healthy Asians show radiological evidence of fatty liver. Asian populations develop insulin resistance and visceral fat accumulation at lower BMI thresholds than Western populations.
Is fatty liver dangerous?
Simple fatty liver carries low immediate risk and is highly reversible. But it's a marker of underlying metabolic dysfunction, which raises your risk of type 2 diabetes and cardiovascular disease over time. What it signals about your broader metabolic health is worth paying attention to.
How often should I get my liver checked?
An annual screening that includes a liver panel and metabolic markers is a reasonable baseline. If any markers are elevated, follow up in 6 months to establish whether it's a one-off or a trend. Tracking results over time matters more than testing frequency.
How can Genie Health help me monitor fatty liver?
Genie's Health Locker lets you upload your health reports and organises your biomarkers by Health Pillars. Liver enzymes like ALT, AST, and GGT, along with metabolic markers like triglycerides, HbA1c, and glucose, show up under Gut and Metabolic Health, and are also accessible under Liver Function in All Biomarkers. When you upload more than one report, you can see trends over time, making it easier to spot patterns a single report would miss. If you have a wearable connected, you can Ask Genie to help you understand how your lifestyle habits relate to your results.

References & Sources

  1. Ngu JH, Goh GBB, Poh Z, Soetikno R. "Managing non-alcoholic fatty liver disease." Singapore Medical Journal 2016; 57(7): 368–370. SGH / Duke-NUS Medical School. http://www.smj.org.sg/article/managing-non-alcoholic-fatty-liver-disease
  2. Razavi H et al. "Modelling NAFLD disease burden in four Asian regions — 2019–2030." Alimentary Pharmacology & Therapeutics 2020; 51(8): 801–811. https://www.cghjournal.org/article/S1542-3565(21)01280-5/fulltext
  3. Rinella ME, Lazarus JV, Ratziu V et al. "A multisociety Delphi consensus statement on new fatty liver disease nomenclature." Journal of Hepatology 2023; 79(6): 1542–1556. AASLD / EASL / ALEH. https://www.aasld.org/new-masld-nomenclature
  4. Fan JG, Kim SU, Wong VWS. "New trends on obesity and NAFLD in Asia." Journal of Hepatology 2017; 67(4): 862–873. https://pubmed.ncbi.nlm.nih.gov/28642059/
  5. Younossi ZM et al. "Global epidemiology of NAFLD — Meta-analytic assessment of prevalence, incidence, and outcomes." Clinical Gastroenterology and Hepatology 2022; 20(12): 2809–2817. https://pmc.ncbi.nlm.nih.gov/articles/PMC7154715/
  6. Health Promotion Board, Singapore. "National Nutrition Survey 2018." https://www.hpb.gov.sg/newsroom/article/national-nutrition-survey-2018-shows-gradual-improvements-in-singaporeans-dietary-habits
  7. Frontiers in Endocrinology 2026. Meta-analysis: MASLD associated with 54% increased risk of cardiovascular events (HR 1.54) and 46% increased cardiovascular mortality (HR 1.46). https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1830594/full
  8. Stine JG et al. NASHFit Trial — 150 min/week moderate aerobic exercise: threefold increase in MASH resolution vs standard care, independent of weight loss. Presented at AASLD Liver Meeting 2024. https://www.hcplive.com/view/jonathan-stine-md-exercise-benefit-mash-independent-weight-loss
  9. American Diabetes Association. "MASLD in People with Diabetes: The Need for Screening and Early Intervention." Diabetes Care 2025; 48(7): 1057. ADA Consensus Report. https://diabetesjournals.org/care/article/48/7/1057/160536/
  10. He K, Phuah P, Kabigting J, Chung Z. "2024 Is A Historic Year for Fatty Liver Disease. What's Next?" Biotech Connection Singapore / ASTAR* June 2024. https://www.biotechconnection-sg.org/2024-historic-year-fatty-liver-disease/
  11. Teng MLP et al. "Global incidence and prevalence of nonalcoholic fatty liver disease." Clinical and Molecular Hepatology 2023; 29(Suppl): S32–S42. https://pmc.ncbi.nlm.nih.gov/articles/PMC10029957/

Read Next: You Only Get 10 Minutes With Your Doctor. Here's How to Make Them Count.

You might also like